A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon alpha2b in patients with suboptimal molecular response or stable detectable molecular residual disease after at least two years of imatinib treatment (NordDutchCML009)

Trial Profile

A phase II, single arm, multicenter study of nilotinib in combination with pegylated interferon alpha2b in patients with suboptimal molecular response or stable detectable molecular residual disease after at least two years of imatinib treatment (NordDutchCML009)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs Nilotinib (Primary) ; Peginterferon alfa-2b (Primary)
  • Indications Chronic myeloid leukaemia
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Acronyms NordDutchCML009
  • Most Recent Events

    • 25 Jun 2017 Results presented at the 22nd Congress of the European Haematology Association
    • 25 Jun 2017 Status changed from recruiting to discontinued as the recruitment of patients was difficult, according the results presented at the 22nd Congress of the European Haematology Association
    • 02 Feb 2017 This trial was discontinued in Netherlands, according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top